Study of Tissue and Blood Samples From Patients With Low-Grade Glioma

Alliance for Clinical Trials in Oncology

Status: Completed

Conditions: Brain and Central Nervous System Tumors

Treatments: Genetic: fluorescence in situ hybridization; Other: flow cytometry; Other: immunohistochemistry staining method; Genetic: polymerase chain reaction; Genetic: loss of heterozygosity analysis

Study type: Observational

Funder types: Other; NIH

Identifiers

NCT01004523

NCCTG-947253

NCCTG-94-72-53

CDR0000406626 (Registry Identifier)

NCI-2009-00689 (Registry Identifier)

Details and patient eligibility

About

RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment.

PURPOSE: This research study is looking at tissue and blood samples from patients with low-grade glioma.

Full description

OBJECTIVES:

• Evaluate the diagnostic and prognostic relevance of alterations of specific chromosomes and chromosomal regions including 7, 9p, 10p, 10q, 13q, 17p, 17q, 19q, 22q, X, and Y, using PCR analysis of microsatellite repeats and FISH.
• Evaluate the diagnostic and prognostic relevance of DNA ploidy by flow cytometric analysis; compare with ploidy determination by FISH.
• Assess the diagnostic and prognostic relevance of various markers of cellular proliferation and cellular function including flow cytometric determination of %S-phase, %G2M, and immunohistochemical evaluation of PCNA, Ki-67, and p53.

Enrollment: 135 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

1. Paraffin-embedded tumor tissue blocks of patients enrolled in NCCTG 86-72-51 or 93-72-02 and who had the diagnosis of low-grade glioma.
2. Patients who have the diagnosis of low-grade glioma with an available paraffin- embedded tumor tissue block enrolled in prospective NCCTG and Mayo studies.

Trial design

135 participants in 1 patient group

Single group

Description:

Previously preserved paraffin-embedded tissue blocks are obtained and used for biomarker studies. Blood samples obtained during treatment are also obtained. Loss of heterozygosity of specific chromosomal regions are performed using PCR analysis of microsatellite repeats (41,118-120) on DNA extracted from the paraffin-embedded archival specimens. FISH and flow cytometry may also be used to assess chromosomal loss of deletion. Immunohistochemistry is also performed.

Treatment:

Genetic: fluorescence in situ hybridization

Genetic: polymerase chain reaction

Genetic: loss of heterozygosity analysis

Other: flow cytometry

Other: immunohistochemistry staining method